Benzinga | Sep 21, 2020 06:06AM EDT

Fennec Announces Issuance Of US Patent For PEDMARK

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled "Anhydrous Sodium Thiosulfate and Formulations Thereof." As suggested by the title, the patent captures the unique anhydrous form of the active ingredient in Fennec's PEDMARK product, as well as related methods of synthesis. This patent is eligible for listing in the U.S Food and Drug Administration (FDA) Orange Book, and reflects Fennec's strategy to expand and diversify its intellectual property portfolio to obtain protection for the PEDMARK product.



PEDMARK was granted Orphan Drug Designation by the FDA in 2004. This designation, along with a patent portfolio that includes a previously issued method of use patent from March 2020 and this recent to-be-issued composition patent, further strengthens the position of PEDMARK as the first potential treatment for the prevention of platinum induced ototoxicity in pediatric patients.